🇺🇸 FDA
Pipeline program

Botulinum Toxin type A (intradermal / submucosal injection at pain area)

FAHZU-2017-025

Phase 3 small_molecule active

Quick answer

Botulinum Toxin type A (intradermal / submucosal injection at pain area) for Trigeminal Neuralgia is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Trigeminal Neuralgia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials